On November 9, 2023 TheraPPI Bioscience SAS, a preclinical biotechnology company developing small molecules that modify protein interactions in oncology, rare diseases and inflammation, reported the company and PULSALYS SAS ("PULSALYS"), Deeptech innovations incubator and accelerator in Lyon and Saint-Etienne, entered into a license agreement for the development of drugs targeting a novel protein interaction in the Ras-MAPK pathway (Press release, TheraPPI, NOV 9, 2023, View Source [SID1234657178]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the license agreement, TheraPPI obtains exclusive and global rights for the development of novel drugs from compounds discovered within Dr Toufic Renno’s team at the Lyon Cancer Research Centre (CRCL: University Claude Bernard Lyon 1, Inserm, Centre Léon Bérard and CNRS) in collaboration with the C3D technology platform of Lyon (Centre for Drug Discovery and Development) and with the support of Hospices Civils de Lyon. The Renno team has discovered a new therapeutic target, a protein-protein interaction (PPI) in the Ras-MAPK pathway, which is critical to cancer development and certain rare diseases. TheraPPI will develop two drug programs targeting this Ras-MAPK protein interaction in oncology and in rare diseases.
"PULSALYS is proud to support this ambitious project, led by TheraPPI Bioscience, which will enable to meet major healthcare challenges through new solutions developed for patients experiencing therapeutic failure. Furthermore, this project illustrates the cohesion and complementarity of the key players in the local oncology ecosystem, bringing together all stakeholders to boost TheraPPI Bioscience’s development," emphasizes Sophie Jullian, President of PULSALYS. Luc Otten, CEO of TheraPPI added: "The exclusive rights on these novel compounds enable TheraPPI to continue building a portfolio of small molecules that target protein interactions against cancer resistance and provide a cure to rare diseases."
Pursuant to the agreement, PULSALYS is entitled to receive milestone and royalty payments, based on the development of drugs targeting a novel Ras-MAPK protein interaction.